Home Medicine Response to: Shift happens: The utility of external quality assessment data in evaluating folate lot changes. doi.org/10.1515/cclm-2025-1569
Article Open Access

Response to: Shift happens: The utility of external quality assessment data in evaluating folate lot changes. doi.org/10.1515/cclm-2025-1569

  • ORCID logo EMAIL logo , and
Published/Copyright: December 8, 2025

To the Editor,

We read with great interest the letter from the UK NEQAS for Haematinics team and appreciate their comprehensive presentation of EQA data supporting the recent observations regarding shifts in serum folate results obtained with the Roche Folate III assay. Their contribution highlights the value of structured post-market surveillance and the importance of collaborative interpretation of analytical performance.

We fully agree that both patient-based statistical tools – such as patient medians – and EQA programs play essential and complementary roles in the early detection of assay drift or Lot-to-Lot variation. Patient median monitoring enables laboratories to detect subtle shifts using real-world clinical samples with high temporal resolution, while EQA data provide an independent, standardised, and externally benchmarked view of analytical performance across platforms, laboratories, and reagent lots. When used together, these approaches strengthen laboratories’ ability to identify potential risks earlier, refine clinical interpretation, and ensure continuity in patient care.

The dataset presented by UK NEQAS for Haematinics further illustrates the importance of transparency regarding reagent and calibrator Lot information, as well as the need for improved digital infrastructure to support automated sharing of such metadata. As the authors note, full visibility of Lot-specific effects is essential not only for understanding analytical changes but also for assessing downstream clinical impact. We strongly support efforts toward greater collaboration among manufacturers, laboratories, EQA providers, and clinicians, and agree that harmonised analytical performance specifications for Lot-to-Lot variation would be beneficial for all stakeholders.

We appreciate the authors’ dedicated work in disseminating these findings and believe their contribution provides an important complement to patient median data and other internal laboratory monitoring strategies. Together, these tools enhance our collective ability to detect analytical shifts, mitigate clinical risk, and ultimately safeguard patient care.


Corresponding author: Anders Larsson, Department of Medical Sciences, Uppsala University, Entrance 61, 2nd Floor, Akademiska Sjukhuset, 751 85, Uppsala, Sweden, E-mail:

  1. Research ethics: Not applicable.

  2. Informed consent: Not applicable.

  3. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  4. Use of Large Language Models, AI and Machine Learning Tools: None declared.

  5. Conflict of interest: The authors state no conflict of interest.

  6. Research funding: None declared.

  7. Data availability: Not applicable.

Received: 2025-11-26
Accepted: 2025-11-26
Published Online: 2025-12-08
Published in Print: 2026-03-26

© 2025 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Reshaping laboratory medicine through technological advances
  4. Reviews
  5. Capillary blood in core laboratories: current and future challenges
  6. Artificial intelligence and machine learning in thrombosis and hemostasis: a scoping review of clinical and laboratory applications, challenges, and future directions
  7. Opinion Papers
  8. Hierarchy of reference interval models: advancing laboratory data interpretation
  9. Reimagining External Quality Assessment for precision medicine: a perspective from biochemistry laboratories
  10. Science, Quality and Value of Laboratory Medicine
  11. Guidelines and Recommendations
  12. Recommendations from the IFCC Working Group on Laboratory Errors and Patient Safety for the Global Adoption of an Essential Quality Indicators Panel in Laboratory Medicine
  13. Addressing the silent epidemic of recreational nitrous oxide use: a position, call to action and recommendations by the European Federation of Clinical Chemistry and Laboratory Medicine Committee on Biological Markers of Nitrous Oxide Abuse
  14. General Clinical Chemistry and Laboratory Medicine
  15. Assessment of drone transport for biological samples: a real-world experience at a tertiary hospital
  16. Impact of an autonomous delivery robot on sample turnaround time in a clinical laboratory: an early evaluation of first implementation
  17. Implementation of an automated alert system of critical results in hospitalized and emergency patients
  18. Comparison of blood sample quality and test results between robotic and manual venipuncture: a pilot study
  19. At-home blood collection for clinical chemistry analyses in a kidney transplant population: a feasibility study
  20. Clinical validation of a DBS-based LC-MS/MS method for 25-hydroxyvitamin D: from lab sampling to home sampling
  21. Comparative analysis of three platforms for serum NfL quantification in healthy controls and MS patients
  22. Uracil in plasma: comparison of two in-house-developed LC-MS/MS methods
  23. Assessment for potential bias in multiplexed IL-10 and TNF-α from plex count
  24. Hematology and Coagulation
  25. A specific-neonatal hemolysis correction model for accurate potassium assessment in blood samples with in vitro hemolysis
  26. Cancer Diagnostics
  27. Analytical verification and comparative assessment of the new Atellica IM high-sensitivity prostate specific antigen assay
  28. Extended verification of an automated MALDI-TOF mass spectrometry system for high throughput serum M-protein measurement
  29. Cardiovascular Diseases
  30. Performance evaluation of a new high-sensitivity cardiac troponin T assay: hs-cTnT (CLIA) assay
  31. Infectious Diseases
  32. Prognostic value of suPAR in sepsis: a potential tool to support patient management in the Emergency Department
  33. Contribution of SuPAR for patients in a situation of uncertainty downstream of emergencies
  34. One copy in one-pot for rapid and accurate SFTSV testing by LAC12b-2M
  35. Corrigendum
  36. Impact of delayed centrifugation on the stability of 32 biochemical analytes in blood samples collected in serum gel tubes and stored at room temperature
  37. Letters to the Editor
  38. Combining the calibrator uncertainty and the long-term measurement uncertainty? A comment to the ISO/TS 20914 guideline
  39. Comparative analysis of plasma p-tau217 immunoassays: challenges for standardization and harmonization
  40. Shift happens: the utility of external quality assessment data in evaluating folate lot changes
  41. Response to: Shift happens: The utility of external quality assessment data in evaluating folate lot changes. doi.org/10.1515/cclm-2025-1569
  42. Innovative closed tube protocol reveals a super critical early preanalytical phase of whole blood glucose stability in routine matrices
  43. Spun citrate samples as a suitable alternative for platelet measurement. Is recollection necessary? A preliminary study
  44. Mass spectrometry reveals limitations of serum immunofixation electrophoresis in monitoring lambda light chain myeloma
  45. A study of the performance of different methods for measuring serum lithium
  46. Congress Abstracts
  47. 47th Annual Conference of the Association for Clinical Biochemists in Ireland (ACBI)
Downloaded on 31.3.2026 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2025-1575/html
Scroll to top button